<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589238</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000579522</org_study_id>
    <secondary_id>SINGAPORE-NCC-0701</secondary_id>
    <nct_id>NCT00589238</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Compared to Weekly Paclitaxel Alone Followed in Both Arms by Doxorubicin and Cyclophosphamide for Operable or Locally Advanced Basal-like Subtype Breast Cancer Correlating BRCA-1 mRNA and Protein Expression With Carboplatin Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, doxorubicin, cyclophosphamide, and&#xD;
      carboplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. It is not yet known whether combination chemotherapy&#xD;
      is more effective with or without carboplatin in treating breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving paclitaxel together with&#xD;
      doxorubicin and cyclophosphamide to see how well it works compared to giving paclitaxel&#xD;
      together with doxorubicin, cyclophosphamide, and carboplatin in treating women with locally&#xD;
      advanced breast cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate tumor pathological complete response rate after neoadjuvant paclitaxel with&#xD;
           vs without carboplatin followed by cyclophosphamide and doxorubicin hydrochloride in&#xD;
           women with basal-type subtype primary breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the clinical and pathological overall response rate.&#xD;
&#xD;
        -  To evaluate safety and toxicity.&#xD;
&#xD;
        -  To evaluate disease-free survival and overall survival.&#xD;
&#xD;
        -  To correlate low BRCA1 expression (protein and mRNA), p53 mutation, positive CK5/6,&#xD;
           positive CK 14, basal-like gene expression profile, and response to carboplatin-based&#xD;
           treatment.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to clinical stage&#xD;
      (T2-3 vs T4). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (standard therapy): Patients receive paclitaxel IV over 1 hour once weekly in&#xD;
           weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV&#xD;
           on days 1, 8, and 15. Treatment with doxorubicin hydrochloride and cyclophosphamide&#xD;
           repeats every 21 days for 4 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (experimental therapy): Patients receive paclitaxel IV over 1 hour and&#xD;
           carboplatin IV over 15 to 20 minutes on days 1, 8, and 15. Treatment with paclitaxel and&#xD;
           carboplatin repeats every 28 days for 4 courses in the absence of disease progression or&#xD;
           unacceptable toxicity. Patients then receive doxorubicin hydrochloride and&#xD;
           cyclophosphamide as in arm I.&#xD;
&#xD;
      All patients will then undergo surgical resection of the tumor.&#xD;
&#xD;
      Patients undergo biopsy for correlative studies. Samples are analyzed for estrogen receptor&#xD;
      and progesterone receptor status, and molecular endpoints (CK 5/6, CK14, p53, BRCA, and EGFR)&#xD;
      by RT-PCR, immunohistochemistry, protein expression, and gene expression profiling.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>Pathological response will be assessed by evaluation of surgical specimen after completion of protocol treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and pathological overall response rates</measure>
    <time_frame>Clinical response: Serial 4 weekly clinical examination; Mammography, breast ultrasound: Baseline, 3 weeks after treatment protocol or documented clinical progression. Pathological response: Evaluation of surgical specimen after protocol treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease-free survival</measure>
    <time_frame>Clinical response: Serial 4 weekly clinical examination; Mammography, breast ultrasound: Baseline, 3 weeks after treatment protocol or documented clinical progression. Pathological response: Evaluation of surgical specimen after protocol treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of each toxicity item</measure>
    <time_frame>Clinical response: Serial 4 weekly clinical examination; Mammography, breast ultrasound: Baseline, 3 weeks after treatment protocol or documented clinical progression. Pathological response: Evaluation of surgical specimen after protocol treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between low BRCA1 expression (protein and mRNA), p53 mutation, positive CK5/6, positive CK14, basal like gene expression profile, and response to carboplatin based treatment</measure>
    <time_frame>Clinical response: Serial 4 weekly clinical examination; Mammography, breast ultrasound: Baseline, 3 weeks after treatment protocol or documented clinical progression. Pathological response: Evaluation of surgical specimen after protocol treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (Standard Arm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Experimental Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Arm 2 (Experimental Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Arm 1 (Standard Arm)</arm_group_label>
    <arm_group_label>Arm 2 (Experimental Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Arm 1 (Standard Arm)</arm_group_label>
    <arm_group_label>Arm 2 (Experimental Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Arm 1 (Standard Arm)</arm_group_label>
    <arm_group_label>Arm 2 (Experimental Arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive basal-type breast cancer meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Locally advanced or operable primary disease &gt; 2 cm, without evidence of&#xD;
                  metastatic disease&#xD;
&#xD;
               -  Clinical T2 (&gt; 2 cm), T3 (&gt; 5 cm), or T4 primary tumors with or without clinical&#xD;
                  lymph node involvement (N0-3)&#xD;
&#xD;
                    -  T4 tumors are defined by any of the following:&#xD;
&#xD;
                         -  Skin ulceration&#xD;
&#xD;
                         -  Satellite nodules&#xD;
&#xD;
                         -  Peau d' orange (skin edema)&#xD;
&#xD;
                         -  Chest wall invasion&#xD;
&#xD;
                         -  Inflammatory breast cancer&#xD;
&#xD;
          -  Her-2/neu 0-1+ by IHC (or negative by fluorescent in situ hybridization if Her-2 2+ by&#xD;
             immunohistochemistry)&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen and progesterone receptor-negative disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 10 years&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/μL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          -  Platelets ≥ 100,000/μL&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 50% as assessed by MUGA scan or 2D echocardiogram&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to paclitaxel, carboplatin, or other agents used in the study&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  Prior malignancies except for basal cell carcinoma of the skin or curatively treated&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  No HIV-positive patients receiving combination antiretroviral therapy&#xD;
&#xD;
          -  No concurrent primary growth factor prophylaxis&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, surgery for&#xD;
             cancer, or experimental medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wong Nan Soon, MBBS, MRCP, FAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Lee Siew Gek</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Centre, Singapore</investigator_affiliation>
    <investigator_full_name>Yap Yoon Sim</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

